Sun Pharma share price today

Sun Pharmaceutical Industries Ltd's share price was ₹1,773.40 at the close on 4 November 2026. It has been rising for 27 weeks. That is 2.3% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,610 and ₹1,991, and at that close it sat 43% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Sun Pharmaceutical Industries Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 5 weeks running.

Over the last 11 years the share price moved +104% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 1 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: foreign funds (FIIs) cut their stake for 7 quarters in a row, indian funds and insurers (DIIs) raised their stake for 7 quarters in a row and revenue up on a year earlier for 12 quarters in a row (every quarter we can compare).

1. Foreign funds (FIIs) cut their stake for 7 quarters in a row

   From 18% to 14.4% of the company by the September 2026 quarter.

2. Indian funds and insurers (DIIs) raised their stake for 7 quarters in a row

   From 18.4% to 22.3% of the company by the September 2026 quarter.

3. Revenue up on a year earlier for 12 quarters in a row (every quarter we can compare)

   In the September 2026 quarter revenue was ₹16,199 crore, +11.9% on a year earlier.

   Why: Revenue rose because India sales grew on more volume and a wider prescriber base, more than offsetting weaker US sales.

   Next results: check whether Ilumya US prescriptions recover after the slowdown, since management expects its actions and a new use to bring back usual growth.

   From the earnings call on 30 Oct 2026.

For July to September 2026 (the quarter ended 30 September 2026), Sun Pharma reported revenue of ₹16,199 crore, up 11.9% from ₹14,478 crore a year earlier, and a profit of ₹1,995 crore, down 36.2% from ₹3,125 crore.

Sun Pharma results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Sun Pharma's management discussed these results on a call held on 30 October 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Sun Pharma closed at ₹1,773.40 on 4 November 2026, up 4.8% from ₹1,691.40 a year earlier (7 November 2025) and up 122.9% over five years. Its highest weekly close since March 2016 was ₹1,990.50 on 31 July 2026.

Sun Pharma share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

562 weekly closes from 11 March 2016 to 4 November 2026.

4 Nov 2026: Sun Pharma closed at ₹1,773.40, down 0.2% on the week and down 1.5% on the month. 30 Oct 2026: Sun Pharma held its results call for July to September 2026. Management guided: FY27 sales growth high single-digit reiterated.

Earlier

• Results for July to September 2026: Revenue up 11.9% and profit down 36.2% on a year earlier.
• 7 Jul 2026: ex-date for a dividend of ₹5 a share.
• 5 Feb 2026: ex-date for an interim dividend of ₹11 a share.

Sun Pharma paid ₹16 a share in regular dividends in the 12 months to 5 November 2026 (2 payments), a yield of 0.90% at the ₹1,773.40 close on 4 November 2026. The last was a dividend of ₹5 a share, ex-date 7 July 2026.

Sun Pharma dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Sun Pharmaceutical Industries Ltd paid out 33% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for July to September 2026, held on 30 October 2026, Sun Pharma's management guided: FY27 sales growth high single-digit reiterated.

“It is really a variety of things. I think there is a bit of market saturation, but frankly, part of it is execution as well.”Richard Asfalg, on the call for July to September 2026

What management guided

• FY27 R&D at 6-7% of sales with sharp second-half ramp.
• Organon close in January to March 2027 to early 2027 subject to remaining conditions.
• Psoriatic arthritis soft launch in November with full launch in following months.
• Ilumya return to typical growth over next few quarters on interventions plus new indication.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 30 October 2026.

What is changing at Sun Pharma, from the latest results and calls: global innovative specialty portfolio scale, india domestic market leadership & volume outperformance and generic semaglutide commercial scaling.

• Global Innovative Specialty Portfolio Scale. Innovative medicines reached US$351 million in April to June 2026, up 12.8% year-on-year and 21.9% of consolidated sales. ⚠ estimate
• India Domestic Market Leadership & Volume Outperformance. India formulations grew 16.0% year-on-year to ₹54,749 million with 8.5% market share. ⚠ estimate
• Generic Semaglutide Commercial Scaling. Sun became the number-two generic Semaglutide injectable player in India and remains the only Indian provider of an auto-injector. ⚠ estimate
• Organon Global Scale & Platform Transformation. The proposed Organon transaction would create a US$12.4 billion revenue entity and goal US$350 million of cost synergies. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown.

Our read after the April to June 2026 results, written 22 August 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.

Price competition or device-component constraints prevent commercial uptake.

Each change stops working if

• Generic Semaglutide Commercial Scaling: Price competition or device-component constraints prevent commercial uptake.
• Organon Global Scale & Platform Transformation: Closing fails, synergy realization is delayed, or established-brand revenue declines faster than planned.

The main risks

• Post-Acquisition Balance Sheet Leverage: Net debt to operating profit would rise to 2.3x post-close, with deleveraging dependent on combined free cash flow. ✓ fact
• US Generic Revenue Erosion & Site Compliance Delays: US sales declined 9.7% year-on-year in April to June 2026 as generic erosion outweighed innovative-medicines growth. ✓ fact
• Effective Tax Rate Normalization: The effective tax rate has normalized toward 25%, creating a continuing profit headwind versus historical low-tax periods. ✓ fact
• Transaction Closing Uncertainty & Shareholder Approval: Organon closing remains subject to shareholder and regulatory approvals. ✓ fact

Our read after the April to June 2026 results, written 22 August 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.

When Sun Pharma reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Ilumya US prescription trend over next few quarters - check whether interventions plus new indication restore typical growth.

Sun Pharma is on 2 of our India lists: Nifty 50 companies and Pharma stocks.

Sun Pharmaceutical Industries Ltd earned ₹1,995 Cr of net profit in the Sep 2026 quarter, −36.2% on the same quarter a year earlier. Full-year FY26 profit was ₹11,509 Cr. Over 10 years profit has grown 7.4% a year on average. That is 12.3% of the quarter's revenue. The same quarter a year earlier earned ₹3,125 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹11,509 Cr (+5.0% on the year before).

Why profit moved: revenue changed +11.9% on a year earlier and the margin moved −2.0 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed +8.1% and revenue +12.2%. Profit is growing slower than sales: rising costs are taking part of the growth.

FY27-Q1. revenue ₹15,300 Cr and profit ₹2,901 Cr as reported.

FY27-Q2. revenue ₹16,199 Cr and profit ₹1,995 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Sun Pharmaceutical Industries Ltd reported ₹16,199 Cr of revenue in the Sep 2026 quarter, +11.9% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 7.5% a year on average. The last full year, FY26, came in at ₹58,462 Cr.

Revenue is everything the company billed its customers in the period.

Why this happened. India formulations represented 36.1% of consolidated sales in Q1 FY27. PharmaTrac growth was 30.4%; management stated volume plus new products contributed the majority and five products were launched.

The last four reported quarters add to ₹61,632 Cr.

FY26 revenue was ₹58,462 Cr, +11.2% on the year before.

Recent pace: the last four quarters grew +12.2% on average, against 7.5% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +12.1%, against +10.7% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +4.8%, against −0.6% a year (accelerating).

FY27-Q1. revenue ₹15,300 Cr and profit ₹2,901 Cr as reported.

FY27-Q2. revenue ₹16,199 Cr and profit ₹1,995 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Sun Pharmaceutical Industries Ltd's operating margin was 29.0% in the Sep 2026 quarter, 2.0 percentage points lower than the same quarter a year ago. Across 13 years it has been between 21.0% and 44.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why this happened. Organon contributes US$6.2 billion revenue, stable 30% EBITDA margin and approximately US$1 billion annual free cash flow before financing. Cost synergies are planned across procurement, G&A and supply chain over two to four years, subject to closing and execution.

Why the margin moved: operating margin changed −2.0 percentage points on the year while gross margin changed +1.5 points. So the drop came mostly from the gross margin, which means input costs and prices charged.

FY27-Q1. revenue ₹15,300 Cr and profit ₹2,901 Cr as reported.

FY27-Q2. revenue ₹16,199 Cr and profit ₹1,995 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Over the last 3 years, 120% of Sun Pharmaceutical Industries Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹12,419 Cr of operating cash against ₹11,509 Cr of profit. After ₹9,582 Cr of spending on assets, ₹2,837 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 120% of profit came in as cash: the cash cycle got 82 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner.

What to look at next: the bigger use of cash is spending on new assets, at 1.8× depreciation over three years. The next section checks what that spending is building.

Sun Pharmaceutical Industries Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 228 days in FY26, down from 310 days in FY21. It spent ₹14,906 Cr on assets over the last 3 years. Customers take 97 days to pay, and stock sits for 363 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Why this happened. The portfolio grew from US$400 million in 2021 to US$700 million currently. Commercial execution depends on reimbursement, interchangeability and pricing dynamics.

At FY26 sales of ₹58,462 Cr, each day of that cycle ties up about ₹160 Cr, so roughly ₹36,519 Cr is tied up in the business at any time.

FY26: customers took 97 days to pay and stock sat for 363 days, about 11.9 months of sales sitting as stock, for a full cycle of 228 days, shorter than FY21's 310.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 363 days. Customers pay about 97 days after that. Suppliers are paid at 232 days. Together that makes the 228-day cycle.

Spending on assets: ₹14,906 Cr over the last 3 years, against ₹8,070 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹3,052 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Sun Pharmaceutical Industries Ltd's P/E is 34.6×, in the middle of its own history: higher than 66% of past readings. Its usual P/E (the middle reading) is 30.8×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹45.70.